Prana moves forward on Alzheimer's treatment
Friday, 05 April, 2002
A treatment for Alzheimer's Disease is one step closer after the successful completion of a Phase II clinical trial by Prana Biotechnology for its drug PBT-1 (Iodochlorhydroxyquin).
The trial was performed on 32 patients. Half of the patients received the drug and half received a placebo, in a randomised double blind study. Full analysis of the results has not been completed.
Earlier studies in transgenic animals were published last year in the journal Neuron.
Prana's Executive Chairman, Geoffrey Kempler, said that as the current study was being prepared for publication, the company could not comment further on the results at this point in time.
Kempler said the company was pleased with the results, "It has given us a vote of confidence to keep moving forward."
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
